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Abstract
Background Calcimimetics, shown to control biochemical parameters of secondary hyperparathyroidism (SHPT), have wellestablished safety and pharmacokinetic profiles in adult end-stage renal disease subjects treated with dialysis; however, such
studies are limited in pediatric subjects.
Methods In this study, the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cinacalcet were
evaluated in children with chronic kidney disease (CKD) and SHPT receiving dialysis. Twelve subjects received a single
dose of cinacalcet (0.25 mg/kg) orally or by nasogastric or gastric tube. Subjects were randomized to one of two parathyroid hormone (PTH) and serum calcium sampling sequences: [(1) 2, 8, 48 h; or (2) 2, 12, 48 h] and assessed for 72 h after
dosing.
Results Median plasma cinacalcet tmax was 1 h (range 0.5–4.0 h); mean (SD) Cmax and AUClast were 2.83 (1.98) ng/mL and 11.8
(8.74) h*ng/mL, respectively; mean (SD) half-life (t1/2) was 3.70 (2.57) h. Dose adjustments, based upon body weight (mg/kg),
minimized the effects of age, body weight, body surface area, and body mass index on cinacalcet PK. Reductions in serum PTH
levels from baseline were observed at 2 to 8 h post-dose (median 10.8 and 29.6%, respectively), returned towards baseline by 12–
72 h and were inversely related to changes in the plasma cinacalcet PK profile. Single-dose cinacalcet was well-tolerated with no
unexpected safety findings and a PK/PD, safety profile similar to adults.
Conclusions In conclusion, a single 0.25 mg/kg dose of cinacalcet was evaluated to be a safe starting dose in these children aged
< 6 years.
Keywords Calcimimetics . Cinacalcet . Chronic kidney disease . Parathyroid hormone . Pediatric dialysis patients . Secondary
hyperparathyroidism

Introduction
* Winnie Y. Sohn
wkim@amgen.com
1

Amgen, Inc., One Amgen Center Dr. M/S 38-4-A, Thousand
Oaks, CA 91320, USA

2

UCSF Benioff Children’s Hospital, San Francisco, CA, USA

3

David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

4

S. Shahinfar Consulting and Childrens Hospital of Philadelphia,
Philadelphia, PA, USA

5

Children’s Mercy Hospital, Kansas City, MO, USA

Chronic kidney disease-mineral and bone disorder (CKDMBD) is a systemic disorder of mineral and bone metabolism due to CKD manifested by abnormalities of calcium,
phosphorus, parathyroid hormone (PTH), or vitamin D metabolism; abnormalities of bone turnover, mineralization,
volume, linear growth, or strength; and vascular or other
soft tissue calcification [1, 2]. Secondary hyperparathyroidism (SHPT) develops in the course of CKD, and its prevalence and severity increase as CKD progresses towards
end-stage renal disease (ESRD) [3–7]. Secondary
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hyperparathyroidism is associated with adverse outcomes
including cardiovascular complications, vascular calcification, heart failure, calciphylaxis, bone pain, bone deformities, and increased risk of fracture [7–11]. The long-term
consequences of CKD-MBD on the growing skeleton are
characterized by changes in the cardiovascular system,
bone, disordered skeletal development, and growth impairment [12–15]. The overall mortality rate in children with
ESRD is 30-fold greater than in their healthy peers, with a
large proportion of the mortality due to cardiovascular disease (CVD) [16].
Active vitamin D (1,25(OH)2D3), vitamin D analogs,
and phosphate binders are the most common treatments
for SHPT; however, such therapies may not fully treat
SHPT and have the potential to increase the risk of vascular
calcification by increasing serum calcium and phosphorus
levels [17]. In addition, fracture risk, bone deformities, and
growth retardation [9] may not adequately respond to active
vitamin D analogs given to suppress SHPT [18], and a bone
mineralization defect is persistent despite therapy with active vitamin D sterols [18]. Finally, whereas parathyroidectomy has been conducted to treat unresponsive SHPT, children (≤ 17 years of age) have significantly higher general
and endocrine-specific complication rates after parathyroidectomy than adults [19, 20]. Interestingly, children
aged ≤ 6 years have been found to have significantly longer
hospital stays and higher complication rates than children
aged 7–12 years and 13–17 years [19].
Cinacalcet (Sensipar®/Mimpara®, Amgen Inc.,
Thousand Oaks, CA) is a first in-class calcimimetic that is
indicated for the treatment of SHPT in adult subjects with
CKD receiving dialysis [21]. The safety and efficacy of
cinacalcet in adults with CKD and SHPT receiving dialysis
has been extensively investigated [22–25], and its use,
along with calcitriol, or vitamin D analogs, or a combination thereof, is included in the Kidney Disease Improving
Global Outcomes (KDIGO) clinical practice guidelines for
PTH lowering in adult subjects with stage 5 CKD receiving
dialysis [1]. While calcimimetics have been shown to effectively control biochemical parameters in adult ESRD
subjects with associated SHPT receiving dialysis, and severe SHPT with hypercalcemia after renal transplantation
[26], the safety and efficacy of these agents in children
needs to be further investigated [10]. In addition, while
single-dose safety, pharmacokinetic (PK), and pharmacodynamic (PD) data have been published for children >
6 years of age, similar data from younger children have
not previously been reported [27–29].
The objectives of this study were to evaluate the safety,
tolerability, PK, and PD effects of cinacalcet after a single
dose to pediatric subjects aged 28 days to < 6 years with
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CKD receiving dialysis. In addition, the study evaluated the
safety of a 0.25 mg/kg starting dose, in pediatric subjects
under the age of 6 years.

Methods
We conducted a phase 1, open-label study designed to evaluate the safety, tolerability, PK, and PD of cinacalcet in
subjects aged 28 days to < 6 years with CKD and SHPT
undergoing hemodialysis or peritoneal dialysis. The study
was conducted in seven centers located in four countries.
The first subject was enrolled on January 25, 2011, and the
completion date was August 25, 2015 (Fig. 1).
Twelve subjects (< 6 years old) who met inclusion and
exclusion criteria (Table 1) were enrolled to receive a single
dose of 0.25 mg/kg cinacalcet. Cinacalcet was supplied as
5-mg capsules that were not to be swallowed whole. The
capsules were opened and the contents mixed with purified
water or USP-NF sucrose syrup and administered orally
(syringe) or by nasogastric or gastric (NG/G) tube. If possible, subjects fasted from 2 h pre-dose to 2 h post-dose on
day 1. If fasting was not possible, the subject’s intake of
food (liquids and solids) was recorded in the electronic case
report form (eCRF). For subjects undergoing dialysis on
study day − 1 through day 4, information pertaining to the
procedure (i.e., date (s), mode of dialysis, start and stop
times, and dialysate composition [amount of calcium and
potassium]) was recorded in the subject’s chart and in the
appropriate eCRF. Based on the available data, half of the
subjects received peritoneal dialysis and the other half received hemodialysis. It should be noted that hemodialysis
or peritoneal dialysis does not impact cinacalcet PK or PD
response [30]. All subjects received active vitamin D; two
subjects (one in the 28 days to < 3 year age group and
another in the ≥ 3 to < 6 year age group) received
calcium-based phosphorus binders (Ca carbonate).
Blood sampling at pre-defined time intervals post-dose was
performed to assess cinacalcet pharmacokinetics and
pharmacodynamics.

Assessments
Blood samples were collected to measure PTH using an
immunometric assay (ADVlA Centaur PTH Assay,
Siemens Healthcare, Erlangen, Germany), total serum calcium, and albumin 1 day before (day − 1) cinacalcet was
administered. Serum calcium was reported as total calcium
or as the albumin-corrected value by the central laboratory
based on calcium and albumin concentrations. In addition,
ionized calcium was measured in whole blood samples to

Pediatr Nephrol (2019) 34:145–154
Table 1

Inclusion and exclusion criteria

Key inclusion criteria
Age 28 days to < 6 years with CKD and sHPT, undergoing
hemodialysis or peritoneal dialysis at screening (subjects ≥ 6 months
should have been receiving dialysis for ≥ 1 month)
Free of any disease or condition (other than those diseases or conditions
related to their renal disease)
Body weight ≥ 6 kg at screening and at day − 1; gestational age
30 weeks; physical examination must be acceptable to investigator at
screening and at day − 1
Serum calcium within age-appropriate normal ranges per NKF-K/DOQI
guidelines at screening and at day − 1
Hemoglobin ≥ 8 g/dL at screening and at day − 1
Normal or clinically acceptable ECGs at screening and at day 1
Key exclusion criteria
Current or historic malignancy
Cardiac ventricular arrhythmias within 28 days prior to screening
A gastrointestinal disorder or surgery that could affect drug absorption
(e.g., pyloric stenosis or any gut-shortening surgical procedure prior to
screening)
A new onset of seizure or worsening of a pre-existing seizure disorder
within 2 months prior to IP administration
Major surgery (defined as any surgical procedure that involves general
anesthesia or respiratory assistance) within 28 days prior to screening
Received therapy with cinacalcet within 1 month prior to randomization
Clinical lab signs of hepatic impairment
Medications: use of grapefruit juice, herbal medications, or potent CYP
3A4 inhibitors (e.g., erythromycin, clarithromycin, ketokonazole,
itraconazole) within 14 days prior to enrollment and during study
Concurrent or within 28 days prior to enrollment use of medications that
are predominantly metabolized by the enzyme CYP2D6 with a narrow
therapeutic index; use of medications that prolong QT interval
CKD chronic kidney disease, sHPT secondary hyperparathyroidism,
NKF-KDOQI National Kidney Foundation Kidney Disease Outcomes
Quality Initiative, ECG electrocardiogram, IP intraperitoneal

rapidly and efficiently monitor calcium status (e.g.,
normocalcemia, hypocalcemia). For all subjects, blood
samples for PK and PD analyses were collected pre-dose.
Subjects were randomized to undergo one of two sampling
sequences post-dose: (1) sampling at 2, 8, and 48 h; or (2)
sampling at 2, 12, and 48 h. Subjects were assessed clinically, including safety monitoring, for up to 72 h after dosing. Subjects were monitored carefully for the occurrence
of hypocalcaemia (clinical symptoms, as well as serum calcium levels). In the event that serum calcium levels decreased below 8.4 mg/dL (2.1 mmol/L) and/or symptoms
of hypocalcaemia occurred, the following options were recommended to investigators: calcium-containing phosphate
binders, vitamin D sterols, and/or adjustment of dialysate
calcium concentrations to raise serum calcium, according
to clinical judgment. Serum phosphate was managed to
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achieve concentrations within age-appropriate ranges per
National Kidney Foundation-Kidney Disease Outcomes
Quality Initiative (NKF-K/DOQI) guidelines [1].
For determination of plasma cinacalcet concentrations,
plasma samples were obtained and analysis was performed
using high-performance liquid chromatography followed
by tandem mass spectrometric detection (LC-MS/MS) at
Covance (Madison, WI). The calibration standards and QC
samples were interspersed with study samples within each
analytical run, with a validated analytical range of 0.100 to
25 ng/mL. A total of 130 samples were analyzed and the
overall precision and (mean) accuracy of the QC samples
of all analytical runs were within the acceptance criteria. All
study samples were analyzed within the known stability period of 347 days when stored at − 10 to − 30 °C.
Pharmacokinetic (PK) analyses were conducted using
Pharsight Knowledgebase Server system version 4.0.3
(Pharsig ht®, St. L ouis, MO). Cina calc et pla sma
concentration-time data was used to determine the PK parameters using non-compartmental methods (Phoenix
WinNonlin v.6.4 software on Citrix [Pharsight®, St.
Louis, Missouri]). Plasma concentrations below the lower
limit of quantification (LLOQ; 0.100 ng/mL) were set to
zero for the estimation of PK parameters for each subject
and for the calculation of summary statistics at each time
point. Actual dosing and sampling times were used for all
calculations.

Study endpoints
The primary endpoint of the study was the incidence of
treatment-emergent adverse events (AEs), clinically significant changes in physical examinations, laboratory safety
tests, electrocardiograms (ECG), and vital signs. The secondary endpoints included the PK parameters of cinacalcet
(area under the plasma concentration-time curve (AUC),
maximum observed plasma concentration (Cmax), time to
Cmax [tmax], and half-life [t1/2]) and PD parameters of PTH
and serum levels of calcium (total calcium, albumin
corrected serum calcium [cCa], and ionized calcium).
Safety endpoints included nature, frequency, severity, and
relationship to treatment of all AEs; incidence of hypocalcemia; and vital signs and changes in laboratory parameters, including clinical chemistry.

Statistical analysis and determination of sample size
The sample size was based on the variability of change from
baseline in serum calcium in response to cinacalcet administered to pediatric patients 6 to < 18 years (Amgen Study
20030227) throughout the efficacy assessment phase (EAP),
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weeks 17–20. A power analysis of data collected from 12
subjects (standard deviation = 0.53 mg/dL) was calculated
to have 80% power to detect a 0.48 mg/dL reduction in serum
calcium from baseline (α = 0.05, two-sided). Descriptive
statistics were provided for selected demographic, safety,
PK, and PD data for all subjects. Descriptive statistics on
continuous data included means, medians, standard deviations, and ranges, while categorical data were summarized
using frequency counts and percentages.

Safety monitoring and review
Treatment emergent AEs were grouped by system organ
class and by preferred term within system organ class according to the Medical Dictionary for Regulatory Activities
(MedDRA) AE-preferred term dictionary version 18.0.
Determination of the severity of all AEs was consistent
with Common Terminology Criteria for Adverse Events
(CTCAE) V. 4.0 unless specified otherwise. The number
and percent of subjects reporting at least one treatmentemergent AE and each treatment-emergent AE were summarized by system organ class and preferred term over all
subjects and further classified by relationship to treatment.
Tables of Bon-study^ deaths, serious AEs, and early withdrawals due to AEs were provided when necessary.

Results
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including 1 (25%) of 4 subjects < 3 years old, and 2 (25%)
of 8 subjects ≥ 3 years to < 6 years old. There were no serious or fatal AEs. Adverse events reported for one subject
(34 months old) were vomiting, catheter site hemorrhage,
and catheter expulsion. Adverse events reported for two
subjects ≥ 3 years to < 6 years old were increased body temperature (age 61 months) and hypocalcemia (treatment-related adverse event of interest, age 45 months).
There were no life-threatening (grade 4) events reported
during the study. Severe (grade 3) events included one event
each of catheter site hemorrhage, device expulsion (chest
catheter falling out), and hypocalcemia (asymptomatic,
non-serious) that resolved without treatment on day 3 after
start of the treatment. The patient who experienced asymptomatic hypocalcemia (non-serious adverse event, CTCAE
grade 3) on day 1, hour 8 after cinacalcet administration was
a female with baseline total Ca = 2.1 mmol/L; albumin
corrected Ca (cCa) = 2.2 mmol/L, ionized Ca = 0.9 mmol/
L (in the normal range for pediatric subjects) with an elevated baseline PTH of 126.4 pmol/L (1191 pg/mL), and a
phosphorus = 1.71 mmol/L. The patient was undergoing hemodialysis with a dialysate calcium content of 3 mg/dL and
received active vitamin D, Ca carbonate, antihypertensives
(amlodipine, isradipine, labetalol), sevelamer, docusate, sodium polystyrene sulfonate (K binder), and pyridoxine.
Changes observed in laboratory test results (e.g., chemistry
and hematology data) were consistent with the disease states
under study. No notable changes from baseline were observed for vital signs measurements or ECG results.

Demographic and baseline characteristics
Secondary endpoints
Fourteen subjects were initially enrolled into the study including
five subjects 28 days to < 3 years of age and nine subjects ≥
3 years to < 6 years of age. One subject in each age group
discontinued the study prior to receiving cinacalcet. Thus, four
subjects in the original 28 days to < 3 years age group and eight
subjects in the ≥ 3 years to < 6 years age group completed the
study. Among those patients who completed the study, the mean
age was 18.8 months (range 8 to 34 months) for the younger
group subjects (< 3 years), 51.5 months (range 44 to 61 months)
for subjects ≥ 3 years to < 6 years, and 40.6 months (range 8 to
61 months) for all subjects. Mean baseline concentrations of
PTH, corrected calcium, and phosphorus were 536.2 pg/mL,
2.6 mmol/L, and 1.8 mmol/L, respectively; the mean baseline
Ca × P product was 58.6 mg2/dL2.

Primary endpoint
All subjects were monitored for adverse events following a
single oral dose of 0.25 mg/kg cinacalcet. Five treatmentemergent AEs were reported for 3 (25%) of 12 subjects,

Pharmacokinetics
Cinacalcet was rapidly absorbed, with a median tmax of 1 h
(range 0.50 to 4.0 h) (Table 2, Fig. 2). The mean (SD) halflife (t½,z) was 3.70 (2.57) h (Table 2). Plasma cinacalcet
mean (SD) Cmax and AUClast in all subjects < 6 years of
age were 2.83 (1.98) ng/mL and 11.8 (8.74) h*ng/mL, respectively (Table 2). While overall there was no clinically
meaningful difference in cinacalcet exposure between the
age groups due to extensive overlap and high inter-subject
variability (coefficient of variation [CV%] range 54.5 to
75.7) (Fig. 3), there was a trend for slightly higher exposures in subjects ≥ 3 to < 6 years old compared to subjects
< 3 years old. Mean plasma cinacalcet C max and AUC
values appeared to be marginally higher (1.6- to 2.3-fold)
in subjects ≥ 3 to < 6 years old compared with subjects <
3 years old, but individual values were within a similar
range. There were no notable effects of age, weight, body
surface area, and BMI on the PK of cinacalcet, based on an
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Screening
Day -21 to Day -2

Day -1

Pediatric Subjects Aged 28 Days to < 6
Years; Randomized 1:1 to one of the
following PD Sequences:
• 2, 8, 48 hours post-dose
• 2, 12, 48 hours post-dose
N = 12

Day 4

Day 4

Day 30

E
N
D

A
E

S
A
E

O
F
S
T
U
D
Y

F
O
L
L
O
W

F
O
L
L
O
W

U
P

U
P

Fig. 1 Study design and treatment schema. Screening was conducted
between days − 21 to − 2. Subjects entered the clinical unit on day − 1
to undergo safety laboratory testing and baseline PD sampling and
remained in residency until 24-h post-dose procedures were completed. Following pre-dose procedures and dosing on day 1, subjects

underwent a 72-h period of PK, PD sampling, and safety monitoring.
End of study procedures were conducted on day 4 (72 h post-dose). t
SAE follow-up was conducted to day 30. PD pharmacodynamic, PK
pharmacokinetic. AE adverse evemt. SAE serious adverse event

assessment of the impact of these characteristics on
cinacalcet Cmax and AUC values.

to 8 h post-dose (median 10.8% and 29.6%, respectively) and
returned towards baseline by 12 to 72 h (Fig. 4 or Table 3).
Median percent reductions in PTH were greater at 8 h postdose in subjects ≥ 3 years to < 6 years old (− 42.2%) than in
subjects < 3 years old (− 5.2%); however, this observation
should be interpreted with caution given the small subject
numbers (N = 3 and N = 2, respectively) (Fig. 4 or Table 3).
Albumin-corrected serum calcium levels decreased slightly
from baseline, reached nadirs at 8 h post-dose, and subse-

Pharmacodynamics
Baseline PTH values varied widely (10.5–1373.6 pg/mL; median [Q1, Q3] 161 pg/mL [123 pg/mL, 1263 pg/mL]), as there
were no inclusion criteria for minimum PTH levels.
Reductions in serum PTH from baseline were observed at 2
Table 2 Pharmacokinetic
parameter estimates for cinacalcet
in plasma after administration of
0.25 mg/kg cinacalcet to pediatric
subjects < 6 years old with CKD
receiving dialysis

tmax (h)
Subjects < 3 years old
N
4

Cmax (ng/mL)

AUClast (h*ng/mL)

4

4

4

4

Mean (SD)
Median

NR
0.75

1.51 (0.820)
1.36

7.21 (5.27)
6.04

8.31 (6.28)
6.68

2.73 (0.952)
2.60

Min–max
CV%

0.50–3.1
NR

0.797–2.51
54.5

2.84–13.9
73.1

3.29–16.6
75.7

1.83–3.87
34.9

Parameter

AUCinf (h*ng/mL)

t1/2,z (h)

Subjects ≥ 3 to < 6 years old
N
8
8

8

7

7

Mean (SD)
Median
Min–max
CV%

3.50 (2.09)
3.97
0.818–5.75
59.9

14.1 (9.49)
13.7
3.52–28.6
67.3

12.9 (8.60)
9.66
3.90–25.4
66.5

4.26 (3.09)
2.95
2.06–10.6
72.6

12
2.83 (1.98)
2.18
0.797–5.75
70.0

12
11.8 (8.74)
8.96
2.84–28.6
74.1

11
11.3 (7.86)
9.66
3.29–25.4
69.8

11
3.70 (2.57)
2.95
1.83–10.6
69.4

NR
1.0
0.50–4.0
NR

All subjects < 6 years old
N
12
Mean (SD)
NR
Median
1.0
Min–max
0.50–4.0
CV%
NR

AUC area under the plasma-concentration-time curve, AUCinf AUC from time zero to infinity, AUClast AUC from
time zero to time of last quantifiable concentration, CKD chronic kidney disease, Cmax maximum observed plasma
concentration, CV% coefficient of variation, max maximum, min minimum, NR not reported, SD standard deviation, t1/2,z terminal half-life associated with λz, tmax time to maximum concentration
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rum calcium (median percent reductions of up to 6.1% at
12 h post-dose) were observed and were followed by a
return to baseline by the end of study. The overall pattern
of changes from baseline in mean serum calcium and PTH
concentrations was similar for both age groups. Decreased
serum calcium and PTH corresponded inversely to changes
in cinacalcet plasma concentrations up to 8 h after administration. As cinacalcet concentrations declined towards
lower levels (< 0.5 ng/mL), PTH and serum calcium increased and returned to baseline levels by day 3 (Fig. 7).
Safety

quently returned to baseline (Fig. 5). Serum ionized calcium
levels also decreased slightly from baseline, reached nadirs at
8 h post-dose in subjects ≥ 3 years to < 6 years old, at 12 h
post-dose in subjects < 3 years old and subsequently returned
to baseline (Fig. 6).

No major or unexpected safety findings were identified in
this study [27]. Three subjects (25%) experienced nonserious AEs (one subject had asymptomatic hypocalcemia,
one subject had increased body temperature, and one subject experienced vomiting, catheter site hemorrhage, and
expulsion). Overall, no clinically significant changes were
observed in vital signs, hematology parameters, or clinical
chemistry parameters, with the exception of median PTH
and calcium concentrations.

Pharmacokinetic/pharmacodynamic relationships

Discussion

Median percent reductions in plasma PTH concentration
were associated with increases in cinacalcet concentration
immediately after dosing (Fig. 7). Specifically, mean
cinacalcet plasma concentration peaked at 1 h post-dose
and gradually declined to undetectable levels by day 2.
As cinacalcet concentrations declined, plasma PTH concentrations transiently increased and returned to baseline
levels by day 3. As expected, slight reductions in total se-

The present study evaluated the safety of cinacalcet, including the incidence of treatment-emergent AEs and clinically significant changes in physical examinations, laboratory safety tests, electrocardiograms ECG, and vital signs
in dialyzed children < 6 years of age. No subject experienced a serious AE, and three subjects experienced nonserious AEs, including hypocalcemia, body temperature
increase, and vomiting. No additional safety findings were
identified.
We found that the pharmacokinetic parameters for
cinacalcet in pediatric subjects ≤ 6 years of age were similar
to those observed in other studies (unpublished observations) when normalized by dose and body weight.
Overall, no clinically meaningful differences in cinacalcet
exposure were observed between the age groups due to
extensive overlap, high inter-subject variability, and low
plasma levels from 12 to 72 h after dosing (Table 2; Fig.
3). However, cinacalcet exposure levels (Cmax and AUC
values) tended to be higher in subjects ≥ 3 to < 6 years
old than in subjects < 3 years old. Specifically, mean plasma cinacalcet Cmax and AUC values were 1.6- to 2.3-fold
higher in subjects ≥ 3 to < 6 years old compared with subjects < 3 years old. Consequently, mean Cmax (ng/mL) concentrations for the younger age group was ~ 57% lower
than the older age group subjects and AUClast was ~ 49%

Fig. 2 Mean (SD) plasma cinacalcet log concentration-time profiles after
administration of cinacalcet at 0.25 mg/kg to pediatric subjects with
chronic kidney disease receiving dialysis (n = 10–12)

Fig. 3 Mean (SD) plasma cinacalcet log concentration-time profiles by
age group after enteral administration of cinacalcet
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Fig. 4 Median parathyroid
hormone (PTH) percent change
from baseline after administration
of cinacalcet at 0.25 mg/kg to pediatric subjects with chronic kidney disease (CKD) receiving
dialysis

Table 3 Serum parathyroid
hormone (pg/mL) at baseline and
after administration of cinacalcet
Baseline
n
Median
Q1, Q3
Min, max

Age group: < 3 years
(N = 4)

Age group: ≥ 3 years to < 6 years
(N = 8)

Total subjects
(N = 12)

4
268.8
125.1, 869.7
119.1, 1333.0

8
160.8
102.4, 1266.8
10.5, 1373.6

12
160.8
122.6, 1262.6
10.5, 1373.6

6
4.8
− 53.3, 53.0

9
− 10.8
− 18.5, 23.1

− 89.0, 6253.2
135.6

− 89.0, 6253.2
156.2

3
− 42.2
− 54.8, − 29.6
− 54.8, − 29.6

5
− 29.6
− 42.2, − 12.6
− 54.8, 2.3

620.8

355.37

4
30.3
28.5, 9471.7
27.7, 18,912.2
167.1

5
29.4
27.7, 31.2
− 10.0, 18,912.2
171.1

6
31.8
− 42.9, 83.8
− 49.2, 16,816.6
515.6

9
− 5.4
− 42.3, 69.0
− 49.2, 16,816.6
345.4

Day 1, hour 2 (% change)
n
3
Median
− 10.8
Q1, Q3
− 18.5, 19.1
Min, max
− 18.5, 19.1
Day 1 hour 2
331.3
(median)
Day 1 hour 8 (% change)
n
Median
Q1, Q3
Min, max

2
− 5.2
− 12.6, 2.3
− 12.6, 2.3

Day 1, hour 8
244.8
(median)
Day 1, hour 12 (% change)
n
1
Median
− 10.0
Q1, Q3
− 10.0, − 10.0
Min, max
− 10.0, − 10.0
Day 1, hour 12
1199.1
(median)
Day 3 (% change)
n
3
Median
− 15.0
Q1, Q3
− 42.3, 8.4
Min, max
− 42.3, 8.4
Day 3 (median)
345.4

N number of subjects in the analysis set, n number of subjects with non-missing data at the time point of interest
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Fig. 5 Mean (SE) albumin
corrected calcium (cCa) over time
by age group (< 3 years (n = 4);
age ≥ 3 years < 6 years (n = 8); all
subjects (n = 12))

lower. The trend for higher cinacalcet exposure levels in the
older age group is more apparent when examined within the
first 4 h after dosing. Although sample sizes are small, one
possible reason explaining this trend may be a transient and
heightened increase in CYP3A4 expression at or above
mature levels within 1 to 2 years immediately following
birth that would result in similar or greater metabolism of
cinacalcet and consequently lower AUC and Cmax levels in
the younger population [31]. Another possible explanation
of the lower cinacalcet exposure levels in younger children
is that they have a higher proportion of total body water
[32] and thus, a greater volume of distribution of cinacalcet,
resulting in lower measured plasma concentrations. In
agreement with other pediatric studies, there were no notable effects of age, weight, body surface area, and BMI on
the PK of cinacalcet (unpublished observations).
The 0.25 mg/kg dose employed had an observable PD
effect as demonstrated by the lowering of PTH levels
from baseline after cinacalcet administration, with a maximum reduction observed at 8 h post-dose. PTH levels
decreased and were associated inversely with increases
in plasma cinacalcet concentrations. A similar, but milder,
inverse relationship between serum calcium and increased
plasma cinacalcet concentrations was observed; however,

Fig. 6 Mean (SE) ionized calcium (cCa) concentrations over
time by age group (< 3 years (n =
4); age ≥ 3 years < 6 years (n = 8);
all subjects (n = 12))

only one subject had asymptomatic hypocalcemia. These
results are consistent with the PD response and safety
profile for cinacalcet in adults and children 6 to 18 years
of age [27, 29, 33].
The dose used in the current study is approximately half
the adult starting dose based on a milligrams per kilogram
basis and is lower than the mean dose of 0.39 mg/kg previously studied in 12 subjects age 6 to < 18 years with CKD
receiving dialysis, where 2 subjects (17%) experienced
AEs (unpublished observations). In the current study, five
treatment-emergent AEs were reported for 3 (25%) of 12
subjects, including 1 (25%) of 4 subjects < 3 years old, and
2 (25%) of 8 subjects ≥ 3 years to < 6 years old, and all were
mild to moderate in severity. The safety profile and PD
effect observed in the present study are similar to those
observed in a previous cohort of older pediatric subjects
with sHPT on dialysis [27–29].
The main limitation of the current study was the small
sample size, which did not permit extensive subgroup analyses by age, and therefore, no formal statistical testing was
performed. However, the results from this single-dose
study provide valuable safety, pharmacokinetic, and pharmacodynamic information in a particularly young cohort of
pediatric dialysis patients with SHPT.
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Fig. 7 Mean (SE) plasma
cinacalcet, median (Q1, Q3)
parathyroid hormone (PTH) percent change from baseline; mean
(SE) total serum Ca
concentration-time profiles in pediatric subjects with chronic kidney disease (CKD) receiving
dialysis

Conclusions
The observed safety profile and PD response in this study
of cinacalcet in pediatric dialysis patients less than 6 years
of age were consistent with that known for adult subjects
with SHPT and in older pediatric dialysis subjects 6 to <
18 years of age with SHPT. Results from this study demonstrate that a 0.25 mg/kg dose of cinacalcet was found to
be safe and well-tolerated in children under 6 years of
age, and the observed PD response suggests that repeated
doses would result in a clinically meaningful decrease in
PTH levels.
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